Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD

BACKGROUND: This study forms part of the first complete characterization of the dose–response curve for glycopyrrolate (GP) delivered using Co-Suspension™ Delivery Technology via a metered dose inhaler (MDI). We examined the lower GP MDI dose range to determine an optimal dose for patients with mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabbri, Leonardo M., Kerwin, Edward M., Spangenthal, Selwyn, Ferguson, Gary T., Rodriguez-Roisin, Roberto, Pearle, James, Sethi, Sanjay, Orevillo, Chad, Darken, Patrick, St. Rose, Earl, Fischer, Tracy, Golden, Michael, Dwivedi, Sarvajna, Reisner, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009486/
https://www.ncbi.nlm.nih.gov/pubmed/27586537
http://dx.doi.org/10.1186/s12931-016-0426-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009486/
https://www.ncbi.nlm.nih.gov/pubmed/27586537
http://dx.doi.org/10.1186/s12931-016-0426-4

Ejemplares similares